The North America market for Influenza Vaccine is expected to grow between 2023 and 2032, due to factors like the seasonality and pandemics, development of quadrivalent vaccines, cell-based and nanoparticle vaccines.
The North America Influenza Vaccine Market was valued at USD XX.XX Million in 2022 and is projected to reach USD XX.XX Million by 2032, registering a CAGR of XX.XX % for the forecast period 2023-2032.
North America Influenza Vaccine Market: Overview
The term influenza refers to a viral illness that affects the respiratory system as a result of the flu. The influenza virus is contagious and spreads by respiratory droplets. It can also be passed from one person to another through physical touch or talk. The increase in government support and surveillance for influenza vaccination on a national and international scale is one of the important drivers driving market expansion. This includes monitoring the availability, distribution, and administration of flu vaccines. Furthermore, the launch of therapeutically effective vaccinations has been made possible by increased government financing and global investment by major industry participants, propelling the influenza vaccine market forward. The term "flu" refers to a viral illness that affects the respiratory system as a result of the flu. The influenza virus is infectious and spreads by respiratory droplets.
North America Influenza Vaccine Market – Covid-19 Analysis
The pandemic of COVID-19 has had a wide-ranging impact on the North American influenza vaccine market. On the one hand, growing awareness of respiratory illnesses and the necessity of vaccination has fueled interest in influenza vaccines. The pandemic highlighted the importance of preventive measures, and public health campaigns underlined the importance of annual flu vaccination to reduce the possibility of influenza and COVID-19 co-occurrence. However, issues such as delays in healthcare services, logistics for vaccine distribution, and the overwhelming focus on COVID-19 response drew attention and resources away from routine immunization efforts, particularly those for influenza. The pandemic also highlighted the importance of a strong vaccination infrastructure and expedited discussions on the development of more adaptable vaccine production systems to effectively respond to new infectious illnesses. Overall, the North America Influenza Vaccine Market is being impacted by a combination of greater knowledge, higher demand, and logistical problems that the healthcare industry is tackling in order to achieve thorough vaccine coverage.
North America Influenza Vaccine Market – Drivers
- Seasonality and pandemics: Seasonality and pandemics are major driving factors in the North American Influenza Vaccine Market. Because of seasonal fluctuations in influenza virus activity, influenza vaccinations must be updated annually to match the circulating strains. Because of this seasonality, there is a consistent demand for influenza vaccines, particularly throughout the fall and winter months, when flu activity normally peaks. Furthermore, the threat of pandemics, as demonstrated by the COVID-19 pandemic, has increased the emphasis on preparedness and the need of immunization. The COVID-19 pandemic has highlighted the importance of a robust and adaptive immunization system to respond to new infectious illnesses. Governments, healthcare organizations, and the general public have become more aware of the value of vaccination not just for seasonal influenza but also as a key preventive strategy during pandemics, which has contributed to the growth and sustainability of the North America Influenza Vaccine Market.
- Development of quadrivalent vaccines: Quadrivalent influenza vaccine development has emerged as a driving force in the North America Influenza Vaccine Market. Unlike typical trivalent vaccines, which target three influenza virus strains (two A strains and one B strain), quadrivalent vaccines protect against four strains (two A strains and two B strains). This breakthrough addresses the issue given by the co-circulation of two distinct influenza B lineages, enabling a more complete and effective resistance against influenza's unpredictable character. The availability of quadrivalent vaccines improves the coverage and precision of influenza protection, which is in line with the virus's changing nature. Healthcare providers and public health organizations are increasingly prioritizing the use of quadrivalent vaccines in order to achieve broader protection and improved prevention, fueling the expansion and adoption of these sophisticated influenza vaccines in the North American market.
- Cell-based and nanoparticle vaccines: The incorporation of cell-based and nanoparticle technologies in the creation of influenza vaccines is a prominent driving force in the North American Influenza Vaccine Market. Cell-based influenza vaccines are created utilizing mammalian cells rather than standard chicken eggs, allowing for a more quick and flexible manufacturing method. This method helps overcome the limits of egg-based production, allowing for a faster response to new influenza strains. Furthermore, the introduction of nanoparticle vaccinations, which use microscopic particles to simulate the virus, allows for increased immune responses and the promise for more broadly protective vaccines. The development of cell-based and nanoparticle influenza vaccines answers the requirement for higher vaccine efficacy, faster production, and adaptability to evolving virus strains, all of which contribute to the growth and expansion of the North American Influenza Vaccine Market. As these technologies advance, they open up new possibilities for more effective and responsive influenza prevention efforts.
By Vaccine Type:
- Inactivated: Inactivated influenza vaccinations, sometimes known as flu injections, are made from viruses that have been destroyed or rendered inactive. These vaccines boost the immune system without causing the flu. Inactivated vaccinations are frequently utilized in North America, particularly in high-risk populations such as the elderly, small children, and people with underlying health issues. Because the inactivated vaccine is administered via injection, it is appropriate for a wide spectrum of people, including those with impaired immune systems. It is an important part of seasonal influenza vaccine efforts, providing protection against common influenza viruses.
- Live Attenuated: In healthy people, live attenuated influenza vaccines include weakened, live influenza viruses that do not cause sickness. These vaccinations, which are often administered as a nasal spray, aim to elicit both mucosal and systemic immune responses. Because the nasal delivery route is more agreeable to children, live attenuated vaccines are frequently used for vaccination. However, live attenuated vaccines are not always recommended for some populations, such as pregnant women or those with compromised immune systems. Despite unique limitations, live attenuated influenza vaccinations add to the variety of preventative measures available in the North American Influenza Vaccine Market, catering to various age groups and preferences.
- Trivalent: Trivalent influenza vaccines are intended to protect against three influenza virus strains: two influenza A strains and one influenza B strain. These vaccinations are a critical component of influenza immunization regimens, and they are normally prescribed based on the predicted three most likely circulating strains for a given flu season. Historically, trivalent vaccinations have been successful in avoiding influenza-related sickness and complications. However, as a result of the obstacles created by the co-circulation of two distinct influenza B lineages, they are changing, leading to the creation and greater usage of more advanced quadrivalent vaccinations.
- Quadrivalent: Quadrivalent influenza vaccinations offer protection against four influenza virus strains, two influenza A and two influenza B strains, which is a substantial improvement above trivalent vaccine. The addition of an additional influenza B strain improves the vaccine's ability to address the diversity of circulating influenza viruses. Quadrivalent vaccines are becoming more popular because they provide greater immunity while also fitting with the dynamic character of influenza. Their use is especially critical in areas where both influenza B lineages circulate. As a result, quadrivalent influenza vaccines have become a standard option in North America, contributing to increased vaccine efficacy and a stronger resistance against seasonal influenza viruses.
- Adult: Adult vaccinations are specifically designed and recommended for people aged 18 and up in the context of influenza vaccination. These vaccines are intended to provide protection against common influenza viruses that pose a danger to adults. Adult influenza vaccines are critical in preventing illness, lowering the severity of symptoms, and limiting consequences associated with influenza, especially among vulnerable populations such as the elderly and those with underlying health disorders. The vaccines' composition and formulation may vary depending on the prevalent influenza strains, and they are administered via injection, ensuring optimal protection for the adult population during flu seasons.
- Pediatric: Pediatric influenza vaccines are designed to satisfy the specific immunological needs of children aged six months to seventeen years. These vaccines are designed to provide good protection against influenza viruses that typically afflict children. Pediatric influenza vaccinations, which can be given as injections or nasal sprays, are designed to elicit strong immune responses while taking into account the unique needs and preferences of children. Protecting children from influenza is critical not only for their own health but also for preventing the virus's spread across communities. To promote safe and effective influenza protection in this demographic, pediatric vaccinations frequently include age-appropriate formulations and dosing schedules.
- Injection: Injection-based influenza vaccinations, which are delivered intramuscularly or subcutaneously, are the most popular and traditional technique of providing influenza protection. These vaccines are typically inactivated or recombinant formulations that induce an immune response by delivering virus fragments or entire, inactivated viruses into the body. The injectable technique is widely accepted and effective, as it ensures that the vaccine is delivered directly into the bloodstream for a systemic immune response. Injection vaccines are appropriate for people of all ages, including adults and children, and are especially important for people who have certain health issues that make other routes of administration ineffective.
- Nasal Spray: Nasal spray influenza vaccines, commonly known as live attenuated vaccines, provide an alternate delivery technique. When injected through the nasal passages, these vaccinations use attenuated live viruses that do not cause sickness in healthy people but do stimulate a protective immune response. Nasal spray vaccines are frequently preferred for pediatric groups and people who are allergic to needles. This method of delivery is thought to be more comfortable, especially for children, and may boost mucosal immunity. It is crucial to highlight, however, that nasal spray vaccines may not be appropriate for certain populations, such as pregnant women or people with impaired immune systems. The availability of both injection and nasal spray alternatives for influenza vaccine delivery allows flexibility in influenza vaccine distribution, appealing to a wide range of preferences and healthcare needs.
By Distribution Channel:
- Hospitals & Pharmacies: The principal avenue for reaching the general population is the distribution of influenza vaccines through hospitals and pharmacies. These healthcare environments give persons seeking vaccination with accessible access points, allowing healthcare experts to deliver vaccines and provide immunization recommendations. Pharmacies, in particular, help to provide universal accessibility by allowing consumers to acquire vaccines during routine visits or special immunization events. Hospitals are critical in reaching high-risk individuals and incorporating influenza vaccination into larger healthcare campaigns.
- Government & Institutional Supply: The involvement of government and institutional supply channels in the delivery of influenza vaccinations is critical, particularly during mass vaccination campaigns and public health programs. Governments purchase and distribute vaccines to guarantee that all demographic groups are covered. Institutional supply entails supplying vaccinations to diverse groups such as schools, companies, and community centers in order to facilitate targeted vaccination initiatives. These channels are critical in carrying out large-scale immunization campaigns, reaching marginalized communities, and improving overall vaccine accessibility.
- Other: Other distribution channels include venues other than hospitals, pharmacies, and government agencies. Clinics, community health centers, and specialty healthcare providers may be included. Vaccine makers may also supply directly to healthcare providers or distribute through wholesalers to reach various locations along the healthcare delivery chain. These many channels contribute to the adaptability and flexibility of influenza vaccine distribution, ensuring that vaccinations are available through several channels to address the specific needs of different populations and circumstances.
North America will have the greatest revenue market share of 53.35% in 2022, owing to improved public knowledge of influenza diseases and available treatments, government education campaigns, and the development of new vaccinations enabled by technical breakthroughs. The presence of major market players in the area, as well as their large R&D spending, are key factors contributing to the market's growth. The influenza pandemic has spread throughout North America, expanding the market. In December 2022, the CDC received reports of about 150,865 influenza-positive cases, with 149,704 instances connected with the influenza A virus and 1,61 with the influenza B virus. Furthermore, according to data issued by the Public Health Agency of Canada in December 2022, roughly 34,413 influenza cases were registered in Canada from August 2022 to December 2022. The high number of influenza illnesses in North America is expected to raise demand for influenza vaccines and drive market expansion in this area.
Snapshot:
| Attributes | Details |
| Market Size in 2022 | USD XX.XX Million |
| Market Forecast in 2032 | USD XX.XX Million |
| Compound Annual Growth Rate (CAGR) | XX.XX % |
| Unit | Revenue (USD Million) and Volume (Kilo Tons) |
| Segmentation | By Vaccine Type, By Indication, By Age Group, By Route of Administration, By Distribution Channel & By Region |
| By Vaccine Type |
|
| By Indication |
|
| By Age Group |
|
| By Route of Administration |
|
| By Distribution Channel |
|
| Base Year | 2022 |
| Historical Year | 2018 - 2022 |
| Forecast Year | 2023 - 2032 |
Competitive Landscape:
List of Prominent Players:
- Pfizer Inc.
- Sanofi
- GlaxoSmithKline
- AstraZeneca
- Merck & Co., Inc.
- CSL Limited
- Johnson & Johnson
- Roche Holding AG
- Daiichi Sankyo Company, Limited
- Novavax Inc.
- Others
By Vaccine Type:
- Inactivated
- Live Attenuated
- Trivalent
- Quadrivalent
- Adult
- Pediatric
- Injection
- Nasal Spray
- Hospitals & Pharmacies
- Government & Institutional Supply
- Other
